1. Home
  2. CL vs REGN Comparison

CL vs REGN Comparison

Compare CL & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CL
  • REGN
  • Stock Information
  • Founded
  • CL 1806
  • REGN 1988
  • Country
  • CL United States
  • REGN United States
  • Employees
  • CL N/A
  • REGN N/A
  • Industry
  • CL Package Goods/Cosmetics
  • REGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • CL Consumer Discretionary
  • REGN Health Care
  • Exchange
  • CL Nasdaq
  • REGN Nasdaq
  • Market Cap
  • CL 73.0B
  • REGN 59.5B
  • IPO Year
  • CL N/A
  • REGN 1991
  • Fundamental
  • Price
  • CL $85.17
  • REGN $573.38
  • Analyst Decision
  • CL Buy
  • REGN Buy
  • Analyst Count
  • CL 12
  • REGN 23
  • Target Price
  • CL $98.67
  • REGN $794.83
  • AVG Volume (30 Days)
  • CL 4.6M
  • REGN 996.9K
  • Earning Date
  • CL 10-24-2025
  • REGN 10-30-2025
  • Dividend Yield
  • CL 2.44%
  • REGN 0.61%
  • EPS Growth
  • CL 3.73
  • REGN 5.03
  • EPS
  • CL 3.56
  • REGN 39.67
  • Revenue
  • CL $19,998,000,000.00
  • REGN $14,214,200,000.00
  • Revenue This Year
  • CL $4.42
  • REGN N/A
  • Revenue Next Year
  • CL $4.34
  • REGN $4.97
  • P/E Ratio
  • CL $23.90
  • REGN $14.45
  • Revenue Growth
  • CL 0.04
  • REGN 5.38
  • 52 Week Low
  • CL $82.40
  • REGN $476.49
  • 52 Week High
  • CL $109.30
  • REGN $1,175.16
  • Technical
  • Relative Strength Index (RSI)
  • CL 50.05
  • REGN 51.26
  • Support Level
  • CL $82.65
  • REGN $559.62
  • Resistance Level
  • CL $84.75
  • REGN $588.70
  • Average True Range (ATR)
  • CL 1.52
  • REGN 17.58
  • MACD
  • CL 0.10
  • REGN -2.29
  • Stochastic Oscillator
  • CL 47.55
  • REGN 27.07

About CL Colgate-Palmolive Company

Since its founding in 1806, Colgate-Palmolive has grown to become a leading player in the household and personal care arena. In addition to its namesake oral care line (which accounts for north of 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and homecare products that are sold in over 200 countries. International sales account for about 70% of its total business, including approximately 45% from emerging regions. It also owns specialty pet food maker Hill's (around one fifth of sales), which sells a majority of its products through veterinarians and specialty pet retailers.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Share on Social Networks: